Alzheimer’s trials need patients. Why are so many screened out?

Alzheimer’s trials need patients. Why are so many screened out? is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Kelly Bilodeau · 2026-10-16

A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing safety.

Source: PharmaVoice